Internal Reference Number: FOI_7272
Date Request Received: 03/07/2023 00:00:00
Date Request Replied To: 27/07/2023 00:00:00
This response was sent via: By Email
Request Summary: Multiple Myeloma
Request Category: Companies
| Question Number 1: Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. | |
| Answer To Question 1: 72 | |
| Question Number 2: Of the multiple myeloma patients over the past 6 month, how many were treated with the following: • Belantamab Mafodotin [Blenrep] • Bortezomib [Velcade] monotherapy or with dexamethasone • Bortezomib, thalidomide and dexamethasone [VTD] • Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) • Carfilzomib [Kyprolis] and dexamethasone • Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone • Daratumumab [Darzalex] monotherapy • Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) • Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) • Elranatamab • Idecabtagene vicleucel [Abecma] • Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) • Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd) • Lenalidomide [Revlmid] monotherapy • Lenalidomide [Revlimid] and dexamethasone • Pomalidomide [Imnovid] and dexamethasone • Selinexor and dexamethasone • Talquetamab • Teclistamab [Tecvayli] • Any other systemic anti-cancer therapy | |
| Answer To Question 2: Q. Of the multiple myeloma patients over the past 6 month, how many were treated with the following: • Belantamab Mafodotin [Blenrep] 0 • Bortezomib [Velcade] monotherapy or with dexamethasone 0 • Bortezomib, thalidomide and dexamethasone [VTD] <5 • Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) <5 • Carfilzomib [Kyprolis] and dexamethasone 0 • Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone 0 • Daratumumab [Darzalex] monotherapy <5 • Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) 19 • Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) 12 • Elranatamab 0 • Idecabtagene vicleucel [Abecma] 0 • Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) 6 • Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd) 18 • Lenalidomide [Revlmid] monotherapy 12 • Lenalidomide [Revlimid] and dexamethasone 0 • Pomalidomide [Imnovid] and dexamethasone 0 • Selinexor and dexamethasone 0 • Talquetamab 0 • Teclistamab [Tecvayli] 0 • Any other systemic anti-cancer therapy <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
